162 related articles for article (PubMed ID: 23964558)
1. Tolerability to etoricoxib in patients with aspirin-exacerbated respiratory disease.
Koschel D; Weber CN; Höffken G
J Investig Allergol Clin Immunol; 2013; 23(4):275-80. PubMed ID: 23964558
[TBL] [Abstract][Full Text] [Related]
2. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
El Miedany Y; Youssef S; Ahmed I; El Gaafary M
Ann Allergy Asthma Immunol; 2006 Jul; 97(1):105-9. PubMed ID: 16892790
[TBL] [Abstract][Full Text] [Related]
3. Long-term tolerability of etoricoxib in patients with previous reactions to non-steroidal anti-inflammatory drugs.
Di Leo E; Aloia AM; Nettis E; Cardinale F; Foti C; Distaso M; Ferrannini A; Vacca A
Int J Immunopathol Pharmacol; 2009; 22(4):1131-4. PubMed ID: 20074479
[TBL] [Abstract][Full Text] [Related]
4. Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs.
Muratore L; Ventura M; Calogiuri G; Calcagnile F; Quarta E; Muratore M; Ferrannini A
Ann Allergy Asthma Immunol; 2007 Feb; 98(2):168-71. PubMed ID: 17304885
[TBL] [Abstract][Full Text] [Related]
5. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease.
Woessner KM; Simon RA; Stevenson DD
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):339-44. PubMed ID: 15521369
[TBL] [Abstract][Full Text] [Related]
6. Etoricoxib challenge in patients with chronic urticaria with NSAID intolerance.
Asero R
Clin Exp Dermatol; 2007 Nov; 32(6):661-3. PubMed ID: 17953635
[TBL] [Abstract][Full Text] [Related]
7. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
Matsumoto AK; Melian A; Mandel DR; McIlwain HH; Borenstein D; Zhao PL; Lines CR; Gertz BJ; Curtis S;
J Rheumatol; 2002 Aug; 29(8):1623-30. PubMed ID: 12180720
[TBL] [Abstract][Full Text] [Related]
8. Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
Dallob A; Hawkey CJ; Greenberg H; Wight N; De Schepper P; Waldman S; Wong P; DeTora L; Gertz B; Agrawal N; Wagner J; Gottesdiener K
J Clin Pharmacol; 2003 Jun; 43(6):573-85. PubMed ID: 12817520
[TBL] [Abstract][Full Text] [Related]
9. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials.
Morales DR; Lipworth BJ; Guthrie B; Jackson C; Donnan PT; Santiago VH
J Allergy Clin Immunol; 2014 Jul; 134(1):40-5. PubMed ID: 24388008
[TBL] [Abstract][Full Text] [Related]
10. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
Ann Allergy Asthma Immunol; 2005 Aug; 95(2):154-8. PubMed ID: 16136765
[TBL] [Abstract][Full Text] [Related]
11. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs.
Doña I; Blanca-López N; Jagemann LR; Torres MJ; Rondón C; Campo P; Gómez AI; Fernández J; Laguna JJ; Rosado A; Blanca M; Canto G
Allergy; 2011 Nov; 66(11):1428-33. PubMed ID: 21834936
[TBL] [Abstract][Full Text] [Related]
12. Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity.
West PM; Fernández C
Ann Pharmacother; 2003 Oct; 37(10):1497-501. PubMed ID: 14519044
[TBL] [Abstract][Full Text] [Related]
13. Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease.
Valero A; Sánchez-López J; Bartra J; Serrano C; Muñoz-Cano R; Roca J; Picado C
Int Arch Allergy Immunol; 2011; 156(2):221-3. PubMed ID: 21597303
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
[TBL] [Abstract][Full Text] [Related]
15. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
Cannon CP; Curtis SP; Bolognese JA; Laine L;
Am Heart J; 2006 Aug; 152(2):237-45. PubMed ID: 16875903
[TBL] [Abstract][Full Text] [Related]
17. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs.
Nettis E; Colanardi MC; Ferrannini A; Vacca A; Tursi A
Ann Allergy Asthma Immunol; 2005 Nov; 95(5):438-42. PubMed ID: 16312166
[TBL] [Abstract][Full Text] [Related]
18. Etoricoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs.
Viola M; Quaratino D; Gaeta F; Caruso C; Valluzzi R; Romano A
Int Arch Allergy Immunol; 2007; 143(2):103-8. PubMed ID: 17228166
[TBL] [Abstract][Full Text] [Related]
19. Effects of selective COX-2 inhibition on allergen-induced bronchoconstriction and airway inflammation in asthma.
Daham K; James A; Balgoma D; Kupczyk M; Billing B; Lindeberg A; Henriksson E; FitzGerald GA; Wheelock CE; Dahlén SE; Dahlén B
J Allergy Clin Immunol; 2014 Aug; 134(2):306-13. PubMed ID: 24461582
[TBL] [Abstract][Full Text] [Related]
20. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
